Renal and Neurologic Benefit of Levosimendan vs Dobutamine in Patients With Low Cardiac Output Syndrome After Cardiac Surgery: Clinical Trial FIM-BGC-2014-01

Renal and Neurologic Benefit of Levosimendan vs Dobutamine in Patients With Low Cardiac Output Syndrome After Cardiac Surgery: Clinical Trial FIM-BGC-2014-01

BackgroundLow-cardiac output syndrome (LCOS) after cardiac surgery secondary to systemic hypoperfusion is associated with a higher incidence of renal and neurological damage. A range of effective therapies are available for LCOS. The beneficial systemic effects of levosimendan persist even after car...

ver descrição completa

Detalhes bibliográficos
Principais autores: Jose L. Guerrero-Orriach, Alfredo Malo-Manso, Marta Ramirez-Aliaga, Ana Isabel Florez Vela, Manuel Galán-Ortega, Isabel Moreno-Cortes, Inmaculada Gonzalez-Almendros, Alicia Ramirez-Fernandez, Daniel Ariza-Villanueva, Juan Jose Escalona-Belmonte, Guillermo Quesada-Muñoz, Enrique Sepúlveda-Haro, Salvador Romero-Molina, Inmaculada Bellido-Estevez, Aurelio Gomez-Luque, Manuel Rubio-Navarro, Juan Alcaide-Torres, Concepcion Santiago-Fernandez, Lourdes Garrido-Sanchez, Jose Cruz-Mañas
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2020-08-01
coleção:Frontiers in Pharmacology
Assuntos:
levosimendan
dobutamine
low cardiac output
kidney
cardiac surgery
Acesso em linha:https://www.frontiersin.org/article/10.3389/fphar.2020.01331/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01331/full

Registros relacionados